Clinical observation of Xiaoaiping injection combined with chemotherapy in treatment of recurrent ovarian cancer / 肿瘤研究与临床

ABSTRACT

Objective To observe the efficacy and safety of Xiaoaiping injection combined with chemotherapy for treatment of recurrent ovarian cancer. Methods Eighty-eight patients with recurrent epithelial ovarian cancer in the Affiliated Cancer Hospital of Shanxi Medical University from October 2014 to November 2016 were randomly divided into the test group (44 cases) and the control group (44 cases) according to the random number table method. The control group was treated with paclitaxel + platinum regimen chemotherapy, and the test group was treated with chemotherapy regimens combined with Xiaoaiping injection. The efficiency and adverse reactions of both groups were compared. Results Finally, 40 patients and 42 patients were enrolled in the test group and the control group respectively. The recent objective response rate (ORR) in the test group was higher than that in the control group [52.5 ％ (21/40) vs. 31.0 ％(13/42), respectively; χ2= 3.919, P= 0.048]. CA12550 ％ declining rate in the test group was higher than that in the control group [75.0％(30/40) vs. 57.1 ％ (24/42); χ2= 2.905, P= 0.088]; CA12575 ％ declining rate in the test group was higher than that in the control group [65.0％(26/40) vs. 28.6％(12/42);χ2=10.934, P=0.001]. The incidence of platelet decline in the test group was lower than that in the control group [7.5％(3/40) vs. 26.2％(11/42);χ2=6.138, P=0.046]. Conclusion Xiaoaiping injection combined with chemotherapy in treatment of recurrent ovarian cancer could increase the recent efficacy and reduce side effects.